Preclinical studies confirm that inhibitors of poly-ADP-ribose polymerases (PARP-1, PARP-2, and PARP-3) may also be helpful in the treatment of CRC and other cancers associated with less common gene mutations such as ATM, CHECK2, PALB2, and RAD51 [11,12,13]. Here, ATM is linked to cancer.